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Abstract
Background Ki-67 expression is a possible risk biomarker and
is currently being used as a response biomarker in
chemoprevention trials. Mammographic breast density is a risk
biomarker and is also being used as a response biomarker. We
previously showed that Ki-67 expression is higher in specimens
of benign breast cells exhibiting cytologic atypia that are
obtained by random periareolar fine needle aspiration (RPFNA).
It is not known whether there is a correlation between
mammographic density and Ki-67 expression in benign breast
ductal cells obtained by RPFNA.
Methods Included in the study were 344 women at high risk for
developing breast cancer (based on personal or family history),
seen at The University of Kansas Medical Center high-risk breast
clinic, who underwent RPFNA with cytomorphology and Ki-67
assessment plus a mammogram. Mammographic breast density
was assessed using the Cumulus program. Categorical
variables were analyzed by χ2 test, and continuous variables
were analyzed by nonparametric test and linear regression.
Results Forty-seven per cent of women were premenopausal
and 53% were postmenopausal. The median age was 48 years,
median 5-year Gail Risk was 2.2%, and median Ki-67 was 1.9%.
The median mammographic breast density was 37%. Ki-67
expression increased with cytologic abnormality (atypia versus
no atypia; P ≤ 0.001) and younger age (≤50 years versus >50
years;  P  ≤ 0.001). Mammographic density was higher in
premenopausal women (P  ≤ 0.001), those with lower body
mass index (P < 0.001), and those with lower 5-year Gail risk (P
= 0.001). Mammographic density exhibited no correlation with
Ki-67 expression or cytomorphology.
Conclusion Given the lack of correlation of mammographic
breast density with either cytomorphology or Ki-67 expression in
RPFNA specimens, mammographic density and Ki-67
expression should be considered as potentially complementary
response biomarkers in breast cancer chemoprevention trials.
Introduction
Established risk factors for the development of breast cancer
include components incorporated into the Gail model, breast
mammographic density, and cellular atypia. Mammographic
density is an important biomarker of risk for the development
of breast cancer and, because it is modifiable, it is a potential
response biomarker as well. Cytologic atypia is an established
risk factor for the development of breast cancer. A prospective
study conducted in high-risk women employed random periar-
eolar fine needle aspiration (RPFNA) to sample breast tissue
[1]. It revealed that women with RPFNA atypia had a fivefold
increased risk for subsequent clinical development of ductal
carcinoma in situ (DCIS) or invasive cancer as compared with
those without atypia, and RPFNA atypia stratified risk based
on the Gail model [1]. Both mammographic density and cellu-
lar atypia are risk biomarkers that can stratify estimates based
on the Gail model but they have limitations, particularly when
they are used as surrogate markers of response, which include
interpretive variance (both biomarkers), lack of categorical
change (cellular atypia), and lack of change with some
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effective interventions compared with placebo in postmeno-
pausal women (mammographic density) [2,3].
Increased proliferation is a fundamental process in carcino-
genesis. Shabaan and coworkers [4], in a cross-sectional
study, observed that women with increased Ki-67 in foci of
hyperplasia were at increased risk for breast cancer. Reduc-
tion in proliferation has been shown to correlate with response
to antihormonal agents in cancer treatment trials [5]. Ki-67
expression is currently being used in phase II breast cancer
chemoprevention trials. The rationale behind the use of Ki-67
as a response biomarker in phase II proof-of-principle trials
would be stronger if correlation could be established with
development of cancer or with other biomarkers associated
with a substantial increase in risk (atypical morphology and
high mammographic density, for instance). On the other hand,
if no strong correlation could be established, then these two
biomarkers may be regarded as independent and potentially
complementary risk or response biomarkers. We have previ-
ously shown that Ki-67 expression in benign epithelial cells is
positively correlated with epithelial cell number and cytomor-
phologic abnormality in women at increased risk for breast
cancer [6]. In this analysis, we examine the correlation
between Ki-67 and mammographic density.
Materials and methods
Study cohort
The study cohort consisted of high-risk women undergoing
baseline eligibility assessment for one of several prevention or
surveillance trials at the University of Kansas Medical Center
Breast Cancer Prevention Center. Women eligible for RPFNA
were those with one of the following risk factors: one first-
degree relative or more with breast cancer diagnosed at less
than 60 years of age; multiple second-degree relatives with
breast cancer; known carrier of a mutation in BRCA1  or
BRCA2; 5-year Gail risk of 1.7% or those whose relative risk
for developing breast cancer was at least three times that in
the general population; prior breast biopsy that had exhibited
atypical hyperplasia or lobular carcinoma in situ; and having
undergone treatment for a prior contralateral invasive breast
cancer or DCIS. All women had a normal mammogram at the
time of aspiration and had undergone no change in hormone
replacement therapy (HRT) or ingested any selective estrogen
receptor modulator or aromatase inhibitor for a period of 6
months before RPFNA. They were required also to have been
at least 1 year from pregnancy, lactation, or any prior chemo-
therapy. This study was performed after approval by the Uni-
versity of Kansas Medical Center Human Subjects Committee.
The participants signed an informed consent form before each
breast aspiration.
Ki-67 and cytomorphology by random periareolar fine 
needle aspiration
RPFNA was performed to obtain breast epithelial cells under
local anesthesia from two sites (upper outer and upper inner
quadrant) and cells were pooled from both breasts [1].
Women with a prior history of DCIS or invasive breast cancer
had RPFNA done only on the uninvolved breast. For premen-
opausal women, all RPFNAs were done on days 1 to 12 (fol-
licular portion) of the menstrual cycle.
Material from all breast aspiration sites for each woman was
pooled in a 15 ml conical tube containing 9 ml CytoLyt (Cytyc,
Boxborough, MA, USA) and 1 ml of 10% neutral buffered for-
malin. Conical tubes were placed on a Verimix Rocker (Barn-
stead International, Dubuque, IA, USA) at low speed. Cells
were then washed with CytoLyt, processed to a pellet, placed
in PreservCyt (Cytyc) for 48 hours, and then processed to at
least three slides using a standard Thin Prep 2000 (Cytyc)
nongynecologic protocol. At least two slides were Papanico-
laou stained, with one used for morphology and one for Ki-67
staining. Slides for both cytomorphology and Ki-67 were
Papanicolaou stained under RNase-free conditions with
hematoxylin, OG-6 and EA-65 (all from Richard Allen Scien-
tific, Kalamazoo, MI, USA), and were prepared on the Thin
Prep Processor. Cytomorphology was assessed by a single
cytopathologist (CMZ), who assigned a categorical assess-
ment of nonproliferative, hyperplasia, borderline hyperplasia
with atypia, or hyperplasia with atypia [7,8], and a Masood
semiquantitative index score [9]. Cytologic assessments were
made without knowledge of the results of the Ki-67 assess-
ment. Only slides in which more than 500 epithelial cells were
visible by Papanicolaou staining were further processed for Ki-
67. After de-staining, antigen retrieval was performed with a
10 nmol/l citrate buffer (pH 6) in a Biocare (Walnut Creek, CA,
USA) decloaking chamber (DC 2002) for 2 min at 120°C.
Slides were stained with a MIB-1 monoclonal antibody
(M7240 Dako Cytomation; Dako, Carpenteria, CA, USA) at a
1:20 dilution using a Dako autostainer [6]. Hyperplastic clus-
ters were preferentially assessed, and the number of cells with
unequivocal nuclear staining out of a total of 500 cells was
assessed manually by two technicians and a consensus score
recorded.
Breast mammographic density assessment
Mammography was performed within 6 months of the RPFNA
procedure. Cranio-caudal views of mammograms were digi-
tized using a Lumisys Lumiscan 85 (Lumisys Inc., Sunnyvale,
CA, USA). Left mammogram was used for assessment except
in women with prior cancer, in which the mammogram of the
unaffected breast was used. All mammograms were assessed
by a single operator (QJK) using the Cumulus computer-
assisted program [10]. The parameters recorded were the
total breast area and the area of breast considered to be at
increased density (both in pixels and cm2). The percentage of
the breast in which density was increased was then calcu-
lated. One mammogram from every batch was a duplicate.
Because there were 12 batches, 12 mammograms were read
twice to determine reproducibility. The R2 for reproducibility
was 0.88.Available online http://breast-cancer-research.com/content/9/3/R35
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Statistical analysis
Frequencies of categorical variables were assessed using χ2
analysis. Continuous variables were assessed using the Mann-
Whitney or Kruskal-Wallis nonparametric test. Multivariate
analyses were conducted using stepwise linear regression.
Results
Included in this analysis were all women at high risk for breast
cancer who had undergone RPFNA for risk assessment or eli-
gibility assessment for one of several clinical chemoprevention
trials between March 2003 and May 2006. This provided 344
evaluable individuals for whom sufficient ductal cells (>500)
were present in the slide designated for Ki-67 and who had a
mammogram for density measurement. Median age was 48
years (range 20 to 78 years). Median height was 1.65 m (1.5
to 1.8 m) and median weight was 68 kg (43 to 119 kg). One
hundred and sixty-two (47%) women were premenopausal
and 182 (53%) were postmenopausal. Among postmenopau-
sal women, 114 (63%) women were on some form of HRT,
including 78 on estrogen alone, nine on estrogen plus testo-
sterone, 27 on estrogen plus progestins (eight with testoster-
one as well).
Ki-67 expression
Median level of Ki-67 expression was 1.9% (range 0% to
33%). There was excellent agreement and low interobserver
variance between the two readers for the 344 specimens (R2
= 0.99). Median Ki-67 was 3.3% among specimens from pre-
menopausal women as compared with 1.2% in specimens
from postmenopausal women (P < 0.001; Table 1). There was
no difference in Ki-67 expression between specimens from
postmenopausal women receiving HRT and specimens from
those who were not on HRT, but only 21% of women on HRT
were on estrogen plus a progestin. Ki-67 expression was
greater in specimens exhibiting cytomorphologic atypia (P =
0.01) and greater cellularity (P = 0.001; Table 2).
Table 1
Correlation of Ki-67 and mammographic density with demographics and 5-year Gail risk
Variable Number (%) Median (interquartile range)
Ki-67 (%) P Mammographic density (%) P
Total 344 1.9 (0.4–4.6) 37 (21–54)
Age (years)
<48 170 3.1 (1.2–6.0) <0.001 40 (23–57) 0.035
>48 174 1.0 (0.2–3.4) 35 (19–52)
Menopause status
Pre/peri 162 (47%) 3.3 (1.0–5.8) <0.001 45 (30–64) <0.001
Post 182 (53%) 1.2 (0.2–3.6) 32 (16–47)
Post and HRT 114 (33%) 1.2 (0.2–4.0) 0.63 35 (20–49) 0.049
Post but no HRT 68 (20%) 1.0 (0.2–3.2) 24 (11–41)
BMI (kg/m2)
<25 166 2.0 (0.6–4.6) 0.76 49 (34–66) <0.001
>25 178 1.8 (0.4–4.4) 29 (11–42)
5-year Gail risk (%)
<2.2 167 2.6 (1.0–6.0) <0.001 43 (28–58) 0.001
>2.2 176 1.2 (0.2–3.6) 33 (17–51)
Live birth
Yes 63 2.2(0.2–5.4) 0.65 45 (32–76) 0.001
No 281 1.8 (0.6–4.4) 36 (30–51)
Prior breast cancer
No 305 2.0 (0.6–4.8) 0.027 38 (22–55) 0.12
Yes 39 1.0 (0.2–3.0) 33 (16–50)
The median (range) age was 48 years (20 to 78 years), the median (range) body mass index (BMI) was 25 kg/m2 (17 to 44 kg/m2), and the 
median (range) 5-year Gail risk was 2.2% (0% to 16%). BMI, body mass index; HRT, hormone replacement treatment.Breast Cancer Research    Vol 9 No 3    Khan et al.
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Mammographic density
The median mammographic density for the entire cohort was
37% (range 0% to 95%). Mammographic density was higher
in premenopausal women than in postmenopausal women
(Table 1). Median mammographic density was 45% in pre-
menopausal women as compared with 32% in postmenopau-
sal women (P < 0.0001; Figure 1). Among postmenopausal
women, median mammographic densities were as follows:
24% in 68 women receiving no HRT; 30% in 78 women taking
estrogen alone; 59% in women taking progestins alone (only
four women); 36% in 16 women taking a combination of an
estrogen and a progestin; and 47% in eight women taking an
estrogen, a progestin and testosterone. The difference
between estrogen alone (32% [85 women]) and estrogen
plus a progestin (40% [24 women]) was of borderline signifi-
cance using the nonparametric test (P = 0.076) but it was not
significant in multivariate analysis. Mammographic density was
higher in younger women (declining from a median of 61% for
women in their 20s to 29% for women older than 60 years; P
= 0.012), in women with a lower 5-year Gail risk (43% for
women with risk <2.2% versus 34% for women with risk
≥2.2%, P = 0.001) and women with lower body mass index
(BMI; 49% for women with BMI <25 kg/m2 versus 29% for
women with BMI ≥25 kg/m2; P < 0.001). On multivariate anal-
ysis, mammographic density was significantly higher in women
with a lower BMI (P < 0.0001), premenopausal women (P =
0.002) and women with lower Gail risk (P = 0.004).
Correlation of mammographic density with Ki-67 and 
cytomorphology
No correlation was seen between percentage mammographic
density and Ki-67 by multivariate analysis using stepwise linear
regression (P = 0.82; Figure 2). Other variables included in
the analysis were age, menopausal status, 5-year Gail risk,
HRT status, BMI, height and weight. Similarly, no association
was observed between mammographic density and cytomor-
phology by traditional methods (atypia versus no atypia),
Masood semiquantitative method and National Cancer Insti-
tute consensus panel criteria. Using the traditional method,
median mammographic density was 36.8% in women with epi-
thelial hyperplasia and 37.5% in women with hyperplasia and
atypia (P = 0.81; Table 2). With the Masood semiquantitative
index, median mammographic densities were 30%, 37%,
40%, 35%, 38% and 44% for Masood scores of 11, 12, 13,
14, 15 and 16, respectively (P = 0.61). Sixty-five women had
a Masood score of 11 and 12 (lowest category) and 109 had
scores of 15 and 16 (highest category). There was no differ-
ence in mammographic density between the lowest and the
highest Masood category. By multivariate analysis, Ki-67 was
higher in specimens with atypia (P  < 0.001) and younger
women (P < 0.001). However, age is highly associated with
Table 2
Correlation of Ki-67 and mammographic density with cytomorphology
Variable Number (%) Ki-67 (median [interquartile range]) P Mammographic density (median 
[interquartile range])
P
Cytomorphology
No atypia 226 (65%) 1.2 (0.2–3.6) <0.001 37 (20–54) 0.81
Hyperplasia with atypia 118 (35%) 3.6 (1.4–5.8) 37 (22–55)
Cytomorphology (Masood score)
11 11 (3%) 0.6 (0–1.8) 0.001a, 0.001b 37 (21–58)
12 54 (16%) 0.92c
13 64 (19%) 1.6 (0.4–4.2) 37 (20–53)
14 106 (31%)
15 95 (28%) 3.4 (1.4–5.4) 38 (22–55)
≥16 14 (4%)
aMasood score 11/12 versus 13/14. bMasood score 13/14 versus 15/16. cMasood score 11/12 versus 15/16.
Figure 1
Cumulative frequency of mammographic density for premenopausal  and postmenopausal women at high risk for breast cancer Cumulative frequency of mammographic density for premenopausal 
and postmenopausal women at high risk for breast cancer.Available online http://breast-cancer-research.com/content/9/3/R35
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menopausal status and Gail risk. If age was omitted from the
model, then Gail risk (P = 0.009) and menopausal status (P =
0.029) exhibited significant association with Ki-67 in addition
to atypia. Table 3 shows the results of linear regression analy-
sis for Ki-67 and for mammographic density.
Discussion
Breast mammographic density is reflective of the amount of
epithelium, stroma and breast fluid relative to fat (which is radi-
olucent). The volume of stroma and collagen in most women
influences density to a greater extent than the amount of
breast epithelium [11,12]. Mammographic density is positively
associated with several other risk factors and biomarkers,
including breast intraepithelial neoplasia [13], serum insulin-
like growth factor-I and growth hormones in premenopausal
women [14], serum prolactin and combined estrogen plus
progestin HRT in postmenopausal women [15,16], and family
history of breast cancer [17].
Boyd and coworkers [10], in a case control study using com-
puter-assisted measurements, found that statistically signifi-
cant increases in breast cancer risk were associated with
increasing mammographic density. The increment in relative
risk for breast cancer for each percentage increase in density
was 2% (P < 0.0001) and the relative risk for greater than
75% density relative to no density was 4.04 (95% confidence
interval 2.12 to 7.69). Breast density is favorably modulated by
some but not all drugs/interventions that are effective in the
prevention and adjuvant treatment of breast cancer. Tamoxifen
was associated with a 14% reduction in absolute breast den-
sity over 54 months, as compared with an 8% reduction for
placebo-treated women in the IBIS-1 (International Breast
Cancer Intervention Study-1) trial [18], in a cohort of women
with greater than 10% density. Changes in mammographic
density favoring tamoxifen were significant only in
premenopausal women and those under the age of 55 years.
Similarly, two years of a low-fat diet was demonstrated to
reduce the area of breast density for premenopausal but not
postmenopausal women [19], despite the observation in the
WINS (Women's Interventional Nutritional Study) study [20]
that such an intervention significantly reduced the risk for
recurrence, including contralateral breast cancer, in
postmenopausal women [20]. Although breast density is
clearly a risk factor for both premenopausal and postmenopau-
sal women, its accuracy in predicting response to a preventive
intervention is less clear, particularly for postmenopausal
women. It seems plausible, based on the evidence, that inter-
ventions associated with reduced density are likely to be effec-
tive preventive agents.
Because prospective prevention intervention studies with can-
cer as an end-point are expensive and lengthy, surrogate
response biomarkers are often used in phase II chemopreven-
tion trials, in which favorable modulation of biomarker by an
agent is taken as support for that agent's ability to reduce the
incidence of cancer. A response biomarker ideally should also
be a risk biomarker in addition to being modifiable. Mammo-
graphic density is an established risk factor for breast cancer,
as noted above, and is modifiable. Ki-67 expression in benign
Figure 2
Lack of correlation between Ki-67 expression and mammographic  breast density Lack of correlation between Ki-67 expression and mammographic 
breast density.
Table 3
Results of linear regression analysis
Dependent variable Independent variable P
Ki-67 Cell number on slide 0.001
Age at RPFNA (inverse) 0.001a
Breast density (%) BMI <0.001
No live birth <0.001
Premenopausal 0.004
5-year Gail risk 0.02
aIf age is omitted, then Gail risk (strong age component) enters as an independent variable (P = 0.012), followed by atypia (P = 0.012) and 
premenopausal status (P = 0.036). BMI, body mass index; RPFNA, random periareolar fine needle aspiration.Breast Cancer Research    Vol 9 No 3    Khan et al.
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breast cells obtained from RPFNA is also a reversible, a poten-
tial risk and a possible surrogate response biomarker. In a
cohort of 147 high risk women, we previously showed that
cytomorphologic atypia in benign breast cells obtained by
RPFNA is associated with increased Ki-67 expression [6].
Median Ki-67 expression was 2.8% in women with RPFNA
atypia as compared with 1.1% in women without atypia. In the
present study, which now includes 344 women, this correla-
tion between Ki-67 and cytomorphologic atypia persists and
corroborates our previously reported data. Whereas prolifera-
tion appears to be linked to cytologic atypia, it is not clear
whether there is a link between mammographic density and
proliferation or cytomorphology. Study of such a correlation is
important because both mammographic density and Ki-67 are
currently being used in breast cancer prevention trials as sur-
rogate response biomarkers [21,22].
We found no correlation between mammographic density and
Ki-67 or mammographic density and cytomorphologic atypia
in benign breast cells in a cohort of high-risk women for whom
sufficient cells from RPFNA were available for both cytomor-
phology and Ki-67 testing. No study has previously been
undertaken to identify such a correlation. Many epidemiologic
studies have evaluated a relationship between mammographic
density and benign breast histology, with some studies show-
ing an association between histology and mammographic
density, whereas others have shown no such association. In a
cohort of women taking part in the Canadian NBSS (National
Breast Screening Study) study [23], proliferative breast dis-
ease was found to be more frequent in women with greater
breast density. A similar association was noted in a study
reported by Bland and coworkers [24]. Two other studies
[25,26], on the other hand, identified no correlation between
histology and mammographic density. In a nested case-control
study within the prospective Breast Cancer Detection Demon-
stration Project, percentage mammographic density and
benign breast disease histology were found to be distinct
breast cancer risk factors. The risk associated with benign
breast disease was not explained by the effects of percentage
breast density, and the risk associated with percentage breast
density was not explained by benign breast histology, suggest-
ing a lack of correlation between the two risk factors [27]. Sev-
eral cross-sectional studies have described an association
between histology and mammographic density, with different
results [25,28-31]. Fisher and coworkers [28] compared his-
tology and mammographic appearance of breast in women
with cancer and women with fibrocystic disease, and found no
association between epithelial change and mammographic
density. They found that mammographic densities were asso-
ciated with fibrosis in breast parenchyma. A similar lack of
association was described by another study [25]. In contrast
to these studies finding no association, Bright and coworkers
[30] reported associations between mammographic density
and epithelial hyperplasia when xerographic and histologic
findings in women with benign breast disease were compared.
Similarly, Urbanski and colleagues [31] described an associa-
tion between atypia and extensive mammographic density.
Association between proliferation in benign breast and mam-
mographic density is less well studied. In a recently reported
study, Ki-67 (MIB-1) expression was assessed in areas of low,
medium, and high mammographic density in benign breast tis-
sue obtained from reduction mammoplasties. Contrary to what
might be expected, Ki-67 expression in epithelial cells was
less in the areas of medium and high density as compared with
the areas of low density [32]. In another prospective study of
association between mammographic density and benign his-
tology [33], mammographically dense and nondense (fatty) tis-
sues contained similar frequencies of hyperplasia with atypia
and proliferative activity, as determined by S-phase percent-
age. These latter observations suggest a lack of strong corre-
lation between mammographic density and proliferative
activity within the breast. Our findings with random tissue sam-
pling are consistent with these findings.
Our cohort of 344 women includes 114 women who were on
HRT, which could be a potential confounding factor. However,
only 16 women were taking a combination of an estrogen and
a progestin. Combined estrogen plus progestin HRT, and not
estrogen alone, is associated with increases mammographic
density in postmenopausal women [15,16]. We therefore do
not believe that HRT status had any significant impact on our
results, namely a lack of correlation between mammographic
density and Ki-67 expression. Our cohort also included 39
women with a history of prior breast cancer. Cancer treatment
such as endocrine therapy or premature menopause from
chemotherapy could potentially have a confounding effect on
our results. However, only 11 women in our cohort had inva-
sive cancer, eight women received chemotherapy, and four
women took tamoxifen. Given the small number of women
receiving interventions that could have confounding effect on
mammographic density, we do not believe that inclusion of
these women in the cohort influenced our findings.
Furthermore, we ran an analysis excluding these women with
prior cancer and there was no difference in the results.
Conclusion
Our findings indicate that mammographic density, cytomor-
phology, and Ki-67 expression are independent variables, and
may be complementary when used as risk predictors or
response biomarkers in breast cancer chemoprevention trials.
Furthermore, our results continue to show that Ki-67 expres-
sion is associated with the risk biomarker cytomorphology in
high-risk women, and thus they provide evidence that Ki-67
may be used as a response biomarker in proof-of-principle
phase II trials.
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